Alemtuzumab‐induced halo naevus‐like hypopigmentation – new insights into secondary skin autoimmunity in response to an immune cell‐depleting antibody-Reference-Cited by-同舟云学术

Alemtuzumab‐induced halo naevus‐like hypopigmentation – new insights into secondary skin autoimmunity in response to an immune cell‐depleting antibody

Published:2020-07-20 Issue:1 Volume:35 Page:
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J. Eur. Acad. Dermatol. Venereol.

Author:

Böhm M.¹^ORCID,Kemp E.H.²,Metze D.¹,Muresan A.M.¹,Neufeld M.¹,Luiten R.M.³,Ruck T.⁴

Affiliation:

1. Department of Dermatology University of Münster Münster Germany

2. Department of Oncology and Metabolism University of Sheffield Sheffield UK

3. Department of Dermatology and Netherlands Institute for Pigment Disorders Amsterdam UMC Amsterdam Institute for Infection and Immunity University of Amsterdam Amsterdam The Netherlands

4. Clinic of Neurology with Institute for Translational Neurology University of Münster Münster Germany

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.16781

Reference10 articles.

1. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy

2. Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond

3. Case of alemtuzumab-related alopecia areata management in MS

4. Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease

5. Detection of Tyrosinase Autoantibodies in Patients With Vitiligo Using 35S-Labeled Recombinant Human Tyrosinase in a Radioimmunoassay

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Morfea en placas múltiples en un paciente con esclerosis múltiple en tratamiento con alemtuzumab;Piel;2022-12

2. A national, multi-center study in Germany to assess implementation of infusion management, treatment satisfaction and quality of life in MS patients receiving alemtuzumab;Multiple Sclerosis and Related Disorders;2022-03

3. Alemtuzumab‐induced Alopecia areata – a case report and systematic literature review of adverse events associated with Alemtuzumab;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2021-05-10